| Title |
Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
|
|---|---|
| Published in |
OncoTargets and therapy, September 2012
|
| DOI | 10.2147/ott.s28911 |
| Pubmed ID | |
| Authors |
Karel Fostier, Ann De Becker, Rik Schots |
| Abstract |
Carfilzomib is a second-generation proteasome inhibitor with well-documented clinical activity as a single agent in patients with relapsed/refractory multiple myeloma. Carfilzomib can partially overcome resistance in bortezomib-refractory patients and has significant efficacy in bortezomib-naïve patients. Responses generally occur rapidly and are durable in the majority of cases. Carfilzomib can be safely administered in patients with renal failure and adverse cytogenetics do not seem to interfere with its activity. Moreover, carfilzomib has the advantage of a favorable safety profile, especially a low incidence of peripheral neuropathy, which is often the dose-limiting factor in thalidomide and bortezomib-based regimens. The most frequently observed high-grade adverse event is cytopenia. However, long-term tolerability is good with no cumulative toxicity. The place of carfilzomib in the treatment of the advanced and the newly diagnosed myeloma patient is currently under examination in several ongoing phase 3 clinical trials. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Belgium | 3 | 5% |
| Germany | 1 | 2% |
| Unknown | 57 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 23% |
| Student > Ph. D. Student | 12 | 20% |
| Student > Master | 9 | 15% |
| Student > Doctoral Student | 7 | 11% |
| Other | 3 | 5% |
| Other | 9 | 15% |
| Unknown | 7 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 31% |
| Agricultural and Biological Sciences | 7 | 11% |
| Chemistry | 6 | 10% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Psychology | 3 | 5% |
| Other | 14 | 23% |
| Unknown | 9 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 August 2015.
All research outputs
#7,959,659
of 25,373,627 outputs
Outputs from OncoTargets and therapy
#431
of 3,016 outputs
Outputs of similar age
#58,387
of 188,177 outputs
Outputs of similar age from OncoTargets and therapy
#5
of 13 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 188,177 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.